CA3033590A1 - Methods of treating diseases associated with repeat dna instability - Google Patents
Methods of treating diseases associated with repeat dna instability Download PDFInfo
- Publication number
- CA3033590A1 CA3033590A1 CA3033590A CA3033590A CA3033590A1 CA 3033590 A1 CA3033590 A1 CA 3033590A1 CA 3033590 A CA3033590 A CA 3033590A CA 3033590 A CA3033590 A CA 3033590A CA 3033590 A1 CA3033590 A1 CA 3033590A1
- Authority
- CA
- Canada
- Prior art keywords
- cag
- repeat
- repeats
- dna
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374072P | 2016-08-12 | 2016-08-12 | |
| US62/374,072 | 2016-08-12 | ||
| PCT/IB2017/054932 WO2018029660A1 (en) | 2016-08-12 | 2017-08-12 | Methods of treating diseases associated with repeat instability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3033590A1 true CA3033590A1 (en) | 2018-02-15 |
Family
ID=60009661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3033590A Pending CA3033590A1 (en) | 2016-08-12 | 2017-08-12 | Methods of treating diseases associated with repeat dna instability |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11672786B2 (enExample) |
| EP (1) | EP3496713B1 (enExample) |
| JP (1) | JP7236707B2 (enExample) |
| CN (1) | CN110381943A (enExample) |
| CA (1) | CA3033590A1 (enExample) |
| WO (1) | WO2018029660A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7084611B2 (ja) * | 2018-04-06 | 2022-06-15 | 国立大学法人大阪大学 | 脊髄小脳変性症31型抑制剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2049664T3 (da) | 2006-08-11 | 2012-01-02 | Prosensa Technologies Bv | Enkeltstrengede oligonukleotider, som er komplementære til repetitive elementer, til behandling af med DNA-repetitiv-ustabilitet associerede lidelser |
| JP5866283B2 (ja) * | 2009-07-28 | 2016-02-17 | サンガモ バイオサイエンシーズ, インコーポレイテッド | トリヌクレオチド反復疾患を治療するための方法および組成物 |
-
2017
- 2017-08-12 CA CA3033590A patent/CA3033590A1/en active Pending
- 2017-08-12 JP JP2019529315A patent/JP7236707B2/ja active Active
- 2017-08-12 EP EP17778331.3A patent/EP3496713B1/en active Active
- 2017-08-12 CN CN201780063252.0A patent/CN110381943A/zh active Pending
- 2017-08-12 WO PCT/IB2017/054932 patent/WO2018029660A1/en not_active Ceased
- 2017-08-12 US US16/325,066 patent/US11672786B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110381943A (zh) | 2019-10-25 |
| US20210283114A1 (en) | 2021-09-16 |
| JP2019524160A (ja) | 2019-09-05 |
| US11672786B2 (en) | 2023-06-13 |
| EP3496713A1 (en) | 2019-06-19 |
| JP7236707B2 (ja) | 2023-03-10 |
| WO2018029660A1 (en) | 2018-02-15 |
| EP3496713B1 (en) | 2024-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nakamori et al. | A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo | |
| US10767178B2 (en) | Compositions and methods of using piRNAS in cancer diagnostics and therapeutics | |
| JP7416852B2 (ja) | Htra1の発現を調節するためのアンチセンスオリゴヌクレオチド | |
| US20220042022A1 (en) | Antisense oligonucleotides for modulating htra1 expression | |
| US11268093B2 (en) | Therapeutic method for huntington's disease | |
| US20220064642A1 (en) | Oligomeric nucleic acid molecule and application thereof | |
| US11672786B2 (en) | Methods of treating diseases associated with repeat instability | |
| WO2019196883A1 (zh) | 一种激活p21基因表达的方法 | |
| US20220372475A1 (en) | Inhibitors Of RNA Editing And Uses Thereof | |
| AU2022288634A9 (en) | Treatment of psoriasis with interferon induced helicase c domain 1 (ifih1) inhibitors | |
| HK40016999A (en) | Methods of treating diseases associated with repeat instability | |
| Ging | Investigating the Role of Modifiers in Trinucleotide Repeat Diseases | |
| NZ749395A (en) | Antisense oligonucleotides for modulating htra1 expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220811 |
|
| EEER | Examination request |
Effective date: 20220811 |
|
| EEER | Examination request |
Effective date: 20220811 |
|
| EEER | Examination request |
Effective date: 20220811 |
|
| EEER | Examination request |
Effective date: 20220811 |